PMO Interview with the Innovator Series: Volume 2

Peter Hirth, PhD

Video Categories: PMO Interview with the Innovator Series

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
July 29, 2015

Personalized Medicine’s Impact on Cancer Care

Dr. Jorge Cortes provides examples of how personalized or precision medicine has positively impacted the approach to cancer care, citing the benefits of FLT3 inhibitors, IDH inhibitors, and MEK inhibitors, and other targeted treatments.

September 20, 2013

The Cost of Personalized Medicine

Jayson Slotnik discusses the cost structure of diagnostics and pharmaceuticals in personalized medicine